Home>Topics>Companies>Gilead Sciences

Gilead Sciences GILD

  1. All
  2. Commentary
  3. Video Reports
  4. Headlines
    1. Gilead patents on costly hepatitis C drug challenged in 5 countries

      Headlines

      Wed, 20 May 2015

      NEW YORK, May 20 (Reuters) - A U.S. group is trying to block patents in five countries for Gilead Sciences Inc 's costly hepatitis C drug Sovaldi, in a bid to give almost 60 million afflicted people access to cheaper generic versions.

    2. Biotech Fans Could Have a Hangover

      Headlines

      Thu, 14 May 2015

      as adding to the fund's position in top holding Gilead Sciences GILD in December 2014 when concerns about a potentially ..... market-cap spectrum, mid-growth fund Eventide Gilead ETGLX at year-end 2014 held roughly 70 stocks

    3. UPDATE 2- Gilead first-quarter profit doubles on strong hepatitis C drug sales

      Headlines

      Thu, 30 Apr 2015

      LOS ANGELES, April 30 (Reuters) - Gilead Sciences Inc on Thursday said its quarterly profit nearly doubled, driven by strong sales of its hepatitis C drugs, as it topped Wall Street estimates.

    4. Gilead 1st-qtr profit doubles on strong hepatitis C drug sales

      Headlines

      Thu, 30 Apr 2015

      April 30 (Reuters) - Gilead Sciences Inc said on Thursday its quarterly net profit nearly doubled, driven by sales of its novel hepatitis C drugs, as it topped Wall Street estimates.

    5. Gilead Sees Strong 1Q, Raises Guidance; High Cash Levels Mean Acquisitions Will Be Tough to Avoid

      Commentary

      Thu, 30 Apr 2015

      our $114 fair value estimate for Gilead Sciences , which reported a 52% increase ..... launch later this year, we believe Gilead 's portfolio and pipeline are diverse ..... patents begin to expire in 2018. Gilead 's $14.5 billion cash balance

    6. Bristol-Myers says hepatitis C drug combination succeeds in study

      Headlines

      Sat, 25 Apr 2015

      April 25 (Reuters) - Bristol-Myers Squibb Co said its experimental drug cured hepatitis C in over 90 percent of patients in combination with Gilead Sciences Inc 's Sovaldi and a commonly prescribed...

    7. EU regulators warn against combining hep C drugs with amiodarone

      Headlines

      Fri, 24 Apr 2015

      April 24 (Reuters) - European health regulators warned on Friday against using Gilead Sciences Inc 's and Bristol-Myers Squibb Co's hepatitis C medicines along with amiodarone, a drug used to regulate the heartbeat of people with heart rhythm disorders.

    8. How Cuba’s Health Care Sector Aims to Gain a Greater Foothold

      Headlines

      Wed, 18 Feb 2015

      countries and contributing to revenues of $1 billion a year in Cuban pharmaceutical exports. YM BioSciences was acquired by Giliad Sciences in 2013, and Singapore-based Innokeys acquired its stake in the joint venture with CIMAB. Iznaga-Escobar is now chief

    9. Gilead drags healthcare shares down on drug price worries

      Headlines

      Wed, 4 Feb 2015

      Feb 4 (Reuters) - Healthcare shares plunged on Wednesday, lead by biotechnology stocks, after Gilead Sciences Inc said it gave health insurers steeper-than-expected discounts on its hepatitis C...

    10. Raising Our Gilead Fair Value Estimate on Higher HCV Treatment Numbers, Despite Higher Discounting

      Commentary

      Wed, 4 Feb 2015

      Gilead Sciences reported fourth-quarter results and ..... the next couple of years, we believe Gilead 's portfolio and pipeline are diverse ..... the firm's wide moat looks secure. Gilead 's $3.8 billion in hepatitis C revenue

    « Prev12345Next »
    Content Partners